

# CITATION REPORT

List of articles citing

**Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor**

**DOI: 10.1046/j.1464-410x.2003.04061.x**  
**BJU International, 2003, 91, 271-7.**

**Source:** <https://exaly.com/paper-pdf/35241822/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
58	The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 15991-7	5.4	190
57	Actions of IGFBP on epithelial cancer cells: potential for new therapeutic targets. <i>Hormone and Metabolic Research</i> , <b>2003</b> , 35, 828-35	3.1	9
56	Development of molecular agents for IGF receptor targeting. <i>Hormone and Metabolic Research</i> , <b>2003</b> , 35, 843-9	3.1	26
55	Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. <i>Anti-Cancer Drugs</i> , <b>2003</b> , 14, 669-82	2.4	60
54	The insulin-like growth factor (IGF) family and breast cancer. <i>Breast Disease</i> , <b>2003</b> , 18, 45-60	1.6	17
53	. <i>Novartis Foundation Symposium</i> , <b>2004</b> ,		
52	Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. <i>Cancer Research</i> , <b>2004</b> , 64, 8620-9	10.1	138
51	Genetics for urologists. <i>BJU International</i> , <b>2004</b> , 94, 232-7	5.6	1
50	Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. <i>Journal of Pathology</i> , <b>2004</b> , 202, 50-9	9.4	65
49	Human prostate cancer risk factors. <i>Cancer</i> , <b>2004</b> , 101, 2371-490	6.4	409
48	Novel Therapies in Prostate Cancer. <i>European Urology Supplements</i> , <b>2004</b> , 3, 63-69	0.9	2
47	Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. <i>Cancer Gene Therapy</i> , <b>2005</b> , 12, 90-100	5.4	98
46	Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. <i>European Urology</i> , <b>2005</b> , 47, 695-702	10.2	23
45	Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. <i>Journal of Controlled Release</i> , <b>2005</b> , 108, 244-62	11.7	120
44	Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 487-99	3.5	26
43	The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1563-71	12.9	144
42	Novel insights into the implication of the IGF-1 network in prostate cancer. <i>Trends in Molecular Medicine</i> , <b>2005</b> , 11, 52-5	11.5	54

41	Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. <i>Modern Pathology</i> , <b>2006</b> , 19, 788-96	9.8	47
40	Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. <i>Oncogene</i> , <b>2006</b> , 25, 6574-81	9.2	50
39	Insulin-Like Growth Factor (IGF) family and prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 58, 124-45	7	120
38	Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 990-5	4.9	31
37	Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1581-9	7.5	43
36	Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model. <i>Hepatology Research</i> , <b>2007</b> , 37, 366-75	5.1	14
35	siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53. <i>Cell Biology International</i> , <b>2007</b> , 31, 156-64	4.5	10
34	Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2008</b> , 40, 497-504	2.8	17
33	Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 589-603	6.4	97
32	Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. <i>FEBS Letters</i> , <b>2009</b> , 583, 1999-2003	3.83	41
31	Implications of insulin-like growth factor-I for prostate cancer therapies. <i>International Journal of Urology</i> , <b>2009</b> , 16, 161-7	2.3	53
30	Targeting the IGF1 axis in cancer proliferation. <i>Expert Opinion on Therapeutic Targets</i> , <b>2009</b> , 13, 1179-92	6.4	62
29	The insulin-like growth factor-I receptor as an oncogene. <i>Archives of Physiology and Biochemistry</i> , <b>2009</b> , 115, 58-71	2.2	144
28	A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. <i>Current Cancer Drug Targets</i> , <b>2009</b> , 9, 354-65	2.8	44
27	Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. <i>Oncology Reports</i> , <b>2009</b> ,	3.5	1
26	Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. <i>Prostate</i> , <b>2010</b> , 70, 206-18	4.2	31
25	The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 332-9	8.7	72
24	Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells. <i>Endocrinology</i> , <b>2010</b> , 151, 1418-27	4.8	21

23	Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. <i>Lung Cancer</i> , <b>2011</b> , 73, 158-65	5.9	17
22	Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. <i>Molecular and Cellular Endocrinology</i> , <b>2011</b> , 344, 1-24	4.4	60
21	Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. <i>BJU International</i> , <b>2011</b> , 107, 1488-99	5.6	18
20	Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro. <i>Molecular and Cellular Biochemistry</i> , <b>2011</b> , 353, 225-33	4.2	11
19	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. <i>Prostate</i> , <b>2011</b> , 71, 525-37	4.2	17
18	The inhibitory effects of NKX3.1 on IGF-1R expression and its signalling pathway in human prostatic carcinoma PC3 cells. <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 493-8	2.8	0
17	Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. <i>Prostate</i> , <b>2013</b> , 73, 801-12	4.2	25
16	Apicidin-resistant HA22T hepatocellular carcinoma cells strongly activated the Wnt/ $\beta$ -catenin signaling pathway and MMP-2 expression via the IGF-IR/PI3K/Akt signaling pathway enhancing cell metastatic effect. <i>Bioscience, Biotechnology and Biochemistry</i> , <b>2013</b> , 77, 2397-404	2.1	21
15	The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2013</b> , 16, 239-47	6.2	5
14	The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells. <i>Asian Journal of Andrology</i> , <b>2013</b> , 15, 753-8	2.8	15
13	Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1925-34	12.9	29
12	Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation. <i>Tumor Biology</i> , <b>2014</b> , 35, 303-13	2.9	13
11	MicroRNA-206 suppresses gastric cancer cell growth and metastasis. <i>Cell and Bioscience</i> , <b>2014</b> , 4, 26	9.8	48
10	Regulation of SOD2 and $\beta$ -arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells. <i>European Journal of Cell Biology</i> , <b>2014</b> , 93, 289-98	6.1	13
9	GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 753-60	4.4	8
8	SUMOylation of insulin-like growth factor 1 receptor, promotes proliferation in acute myeloid leukemia. <i>Cancer Letters</i> , <b>2015</b> , 357, 297-306	9.9	15
7	Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 3432-44	8.2	26
6	A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , <b>2018</b> , 36, 451-457	4.3	15

5	Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro. <i>Hormones and Cancer</i> , <b>2019</b> , 10, 11-23	5	8
4	MicroRNAs as the critical regulators of protein kinases in prostate and bladder cancers. <i>Egyptian Journal of Medical Human Genetics</i> , <b>2021</b> , 22,	2	1
3	Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts. <i>Future Oncology</i> , <b>2005</b> , 1, 93-101	3.6	17
2	Oligonucleotide Scanning Arrays in the Design of Small Interfering RNAs. <b>2004</b> ,		
1	Cell Biology of Prostate Cancer and Molecular Targets. <b>2010</b> , 1-24		